SEC Tracker
Get the app

Biogen BIIB

Biogen reports stock transactions

Sean Godbout, insider filing for BIIB

Form
4
Filed
Importance
Routine
  1. Sean Godbout, Chief Accounting Officer, acquired 27 shares on Oct 2, 2026.
  2. Disposed of 8 shares on Oct 2, 2026.
  3. Received 985 restricted stock units on Oct 1, 2026.
  4. Restricted stock units vest over three years starting Oct 1, 2027.

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Biogen files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Teva Pharmaceutical Industries TEVA public float $18.2B, Jun 30, 2025
  2. INSMED INSM public float $21.1B, Jun 30, 2025
  3. BeOne Medicines ONC public float $14.7B, Jun 30, 2025
  4. United Therapeutics UTHR public float $11.2B, Jun 30, 2025
  5. Roivant Sciences ROIV public float $9.8B, Sep 30, 2025